MedTrace Logo

Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

NCT00682591 · Status: WITHDRAWN · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2009-02-04

No results posted yet for this study

Summary

Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany.

Aims:

\- Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under HCV treatment.

\- Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone

Conditions

  • Chronic Hepatitis C Infection

Sponsors & Collaborators

  • University of Wuerzburg

    lead OTHER

Principal Investigators

  • Michael Scheurlen, MD · Med. Klinik und Poliklinik II, University of Wuerzburg

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00682591 on ClinicalTrials.gov